After graduating from Waseda University in 2020, engaged in the investment banking business at the US investment bank, Houlihan Lokey.
In 2021, he co-founded Dioseve Inc. and became CEO of the company.
Worked as a researcher and associate professor at the Kyushu University School of Medicine from 2015 to 2020. Currently serving as HHMI Special Researcher at the University of Washington in the USA.
In 2021 he co-founded Dioseve Inc. and became the Chief Scientific Officer of the company.
Obtained a Doctorate degree from Azabu University, and worked as a researcher at the Child Health Institute of New Jersey, Shiga University of Medical Science, and University of Pennsylvania.
Joined Dioseve in 2023
Received a Ph.D. in Medicine from the Institute for Frontier Life and Medical Sciences at Kyoto University.
Subsequently engaged in process development, manufacturing, and medical affairs of cell products at biotech ventures and pharmaceutical companies.
Has held the current position since 2024.
Obtained a Doctorate degree from the Graduate School of Agricultural and Life Sciences, The University of Tokyo in 2018 and worked as a pharmacologist in Astellas Pharma Inc.
Joined Dioseve as Senior Scientist in 2023
Obtained Doctorate degree from the School of Biomedical Sciences, the University of Hong Kong in 2021 and continued to work as a post-doctoral fellow in Cheah’s Lab from the same school.
Joined Dioseve in 2022.
Obtained a Doctorate degree from Tsukuba University, and worked as a researcher at the Veterinary Research Institute in Brno, Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg, and The Institute of Agrobiological Sciences, NARO (NIAS) in Tsukuba. Joined Dioseve in 2023.
Graduated from Universiti Kuala Lumpur Royal College of Medicine Perak in 2014 and engaged in research at Kyushu University’s Hayashi Laboratory.
Joined Dioseve as Senior Scientist in 2021.
Obtained a Doctorate degree from Yokohama City University, and worked as researcher at the National Center for Child Health and the Central Institute for Experimental Animals.
Joined Dioseve in 2022.
Obtained a Doctorate degree from the Graduate School of Chemical Sciences and Engineering, Hokkaido University in 2019. Worked at Niigata University and Hokkaido University as a specially-appointed assistant professor.
Joined Dioseve in 2023.
Obtained a Doctorate degree from the Graduate School of Tokyo University of Marine Science and Technology in 2021.
Worked at a company that provides cancer gene-related testing from 2019-2023.
Joined Dioseve in 2024.
Engaged in Sanwa Kagaku Kenkyusho as a Technician in 2013.
Academic Researcher at Kumamoto University in 2019.
Joined Dioseve in 2022.
Graduated from Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kindai university. Working as an embryologist at a fertility clinic. after that worked as a temporary employee at a cancer genetic testing company and a regenerative medicine company. Joined Dioseve in 2024.
Worked as a research assistant at the Microanatomy Laboratory of Tokyo Women’s Medical University in 2018.
Joined Dioseve in 2024.
Graduated from Kyushu University and engaged in clinical development work at Mitsubishi Tanabe Pharma, as mainly development safety responsible person. After retirement, involved in the development of Muse cell. Joined Dioseve in 2024.
Obtained a Doctorate degree from the faculty of medicine, Osaka University in 2017 and worked at Edinburg University as a post-doctoral fellow. In 2020 engaged in Kobayashi Pharmaceutical Co., Ltd.
Joined Dioseve as Senior Scientist in 2022
Graduated from the Department of Biopharmaceuticals, Kyoto Pharmaceutical University.
Launched the Clinical Development Department at Eli Lilly Japan and Parexel International, and since 2015, General Manager of JConsulting Management Department.
Professor Emeritus of Kyoto Univ. since 2018. Graduated from the Graduate School of Medicine, School of Medicine, Nagoya University. Director of Japan Society of Fertilization and Implantation. Director of Japan Society of Assisted Reproduction.
Board Chairman of Japan Society for Uterus Transplantation.
Obtained the degree of Ph.D. at the Faculty of Science, Kyoto University, engaged in several research areas such as neurobiology and celular biology. Joined GlaxoSmithKline Co., Ltd. in 1997 and worked in drug discovery and late phase clinical development. Appointed as an corporate officer of the company in 2011. Appointed as the Chief Scientific Officer of Bonac Corporation in 2021, engaged in the research & development in nucleic acid medicine and corporate management.
